Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and arsenic trioxide

erlotinib hydrochloride has been researched along with arsenic trioxide in 4 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(arsenic trioxide)		Trials
(arsenic trioxide)		Recent Studies (post-2010) (arsenic trioxide)
4,3537863,0333,1191601,507

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Berger, W; Ferk, F; Heffeter, P; Hoda, MA; Jungwirth, U; Karnthaler-Benbakka, C; Knasmüller, S; Kowol, CR; Kryeziu, K1
Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS1
Ahmadian, S; Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Mesbahi, Y; Zekri, A1
Bardania, H; Hosseini, E; Khosravani, F; Kobarfard, F; Mir, H; Mirzaei, A1

Other Studies

4 other study(ies) available for erlotinib hydrochloride and arsenic trioxide

ArticleYear
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:6

    Topics: Acid Anhydride Hydrolases; Animals; Arsenic Trioxide; Arsenicals; BRCA1 Protein; DNA Breaks, Double-Stranded; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasms; Oxides; Phosphorylation; Quinazolines; Rad51 Recombinase; Signal Transduction; Xenograft Model Antitumor Assays

2013
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
    Cell cycle (Georgetown, Tex.), 2013, May-15, Volume: 12, Issue:10

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2013
Targeting of EGFR increase anti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform.
    European journal of pharmacology, 2018, Feb-05, Volume: 820

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; M Phase Cell Cycle Checkpoints; Molecular Targeted Therapy; Oxides; Reactive Oxygen Species

2018
Arsenic trioxide and Erlotinib loaded in RGD-modified nanoliposomes for targeted combination delivery to PC3 and PANC-1 cell lines.
    Biotechnology and applied biochemistry, 2023, Volume: 70, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Oligopeptides; Oxides; PC-3 Cells

2023